-
SQZ Biotechnologies Company OTC Markets EXMKT:SQZB SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Location: 200 Arsenal Yards Boulevard, Watertown, MA, 02472, United States | Website: https://www.sqzbiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
12.1M
Cash
10.19M
Avg Qtr Burn
-18.58M
Short % of Float
3.10%
Insider Ownership
2.10%
Institutional Own.
22.60%
Qtr Updated
09/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SQZ-PBMC-HPV Details Human papillomavirus | Failed Discontinued | |
SQZ-eAPC-HPV Details Human papillomavirus, Solid tumor/s | Failed Discontinued | |
SQZ-AAC-HPV Details Solid tumor/s, Human papillomavirus | Failed Discontinued |